A comparative analysis from the phase 2 BiCAR trial reported that accelerated glofitamab significantly extends survival after anti-CD19 CAR T-cell failure in diffuse large B-cell lymphoma. The study evaluated glofitamab dosing speed and outcomes against contemporary non-bispecific salvage approaches in patients who had progressed after CAR T therapy. The trial’s central message is that re-starting immunologic pressure with a different CD20-directed bispecific can generate meaningful post-CAR T benefit, even in a heavily pretreated, relapse-prone population. The report adds to the growing evidence that the post–CAR T landscape needs multiple mechanisms of action rather than a single default option.
Get the Daily Brief